Free Trial

Li Watsek Analyst Performance

Biotech Analyst at Cantor Fitzgerald

Li Watsek is a stock analyst at Cantor Fitzgerald in the medical sector, covering 10 publicly traded companies. Over the past year, Li Watsek has issued 12 stock ratings, including and buy recommendations. While full access to Li Watsek's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Li Watsek's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
14 Last 3 Years
Buy Recommendations
100.00% 14 Buy Ratings
Companies Covered
10 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy100.0%14 ratings
Hold0.0%0 ratings
Sell0.0%0 ratings

the majority (100.0%) have been Buy recommendations.

Exchange Coverage

ExchangePercentageCount
NASDAQ
100.0% of companies on NASDAQ
10 companies

Li Watsek, an analyst at Cantor Fitzgerald, currently covers 10 companies listed on , with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
10 companies
100.0%

Li Watsek of Cantor Fitzgerald specializes in stock coverage within the Medical sector.

Coverage Industries

IndustryPercentage
MED - BIOMED/GENE
6 companies
60.0%
MED - DRUGS
3 companies
30.0%
PHARMACEUTICAL PREPARATIONS
1 company
10.0%

Li Watsek's Ratings History at Cantor Fitzgerald

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Context Therapeutics Inc. stock logo
CNTX
Context Therapeutics
10/2/2025Initiated Coverage$0.97Overweight
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
9/9/2025Reiterated Rating$23.39Overweight
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
8/8/2025Boost Price Target$183.27$203.00Overweight
Replimune Group, Inc. stock logo
REPL
Replimune Group
7/30/2025Upgrade$7.53Overweight
Replimune Group, Inc. stock logo
REPL
Replimune Group
6/20/2025Initiated Coverage$9.49Overweight
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
5/12/2025Reiterated Rating$155.13$200.00Overweight
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
3/14/2025Initiated Coverage$4.02Overweight
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
2/25/2025Boost Price Target$152.43$200.00Overweight
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
2/11/2025Reiterated Rating$118.94$170.00Overweight
Arvinas, Inc. stock logo
ARVN
Arvinas
2/7/2025Reiterated Rating$19.25Overweight
Acrivon Therapeutics, Inc. stock logo
ACRV
Acrivon Therapeutics
1/31/2025Initiated Coverage$6.12Overweight
ALX Oncology Holdings Inc. stock logo
ALXO
ALX Oncology
1/24/2025Reiterated Rating$1.50Overweight